Improvement in erectile dysfunction in patients undergoing hyperbaric oxygen treatment: A prospective, double-blind, double controlled study
Anıl EKER, Serdar Celik, Elif Ozer, Ismail Basmaci, Ertugrul Sefik, and 3 more
This is a preprint; it has not been peer reviewed by a journal.
https://doi.org/10.21203/rs.3.rs-2070181/v1
This work is licensed under a CC BY 4.0 License
Abstract
Background: Erectile dysfunction (ED) is a worldwide health problem. Oral phosphodiesterase type 5 inhibitors (PDE5I) are used in its first-line treatment. This study aimed to compare the effects of hyperbaric oxygen (HBO) treatment with PDE5I treatment and determine the patient-dependent factors affecting the efficacy of the HBO treatment and duration of action of HBO treatment.
Methods: Adult male patients who presented to the HBO unit for HBO treatment with non-urological indications and had ED based on the International Erectile Function Index (IIEF-5) constituted the target population of this study. Participants were given HBO treatment (Group 1), no treatment (Group 2), or daily oral tadalafil 5 mg treatment (Group 3). The treatment duration was one month. Patients were assessed by IIEF-5 both initially and after the completion of one month.
Results: 102 male patients were included. Among these patients, 40 received HBO treatment, and 31 received daily oral 5 mg tadalafil treatment. Thirty-one patients were assigned to the control group (Group 2). There were significant increases in the mean IIEF-5 scores of the patients in Group 1 and Group 3 (p<0.001, p<0,001). However, there was no significant improvement in Group 2 (p=0,496). Also, the post-treatment IIEF-5 scores of Group 1 and Group 3 were significantly higher than Group 2 (p<0,001). There was no significant difference between the IIEF-5 scores and ∆IIEF-5 values of Group 1 and Group 3 (p=0,166, p=0,093). Evaluation regarding comorbidities revealed that patients with the peripheric vascular disease did not improve with HBO treatment (p=0,285). Analysis concerning the duration of action of HBO treatment revealed that treatment effects subsided in 90% of the patients six months after completion of treatment.
Conclusion: HBO can improve erectile functions, and it can be a reasonable alternative for patients who cannot use PDE5Is due to comorbidities or treatment side effects.
Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal.
As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing.
